Glenn Pierce, M.D., Ph.D.
Glenn Pierce joined Third Rock Ventures in 2016, bringing more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. His portfolio company roles include:
- Interim chief medical officer of Ambys Medicines
- Board member of Global Blood Therapeutics
Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading the hematology, cell and gene therapies division. At Biogen, Glenn spearheaded the initiation of the Humanitarian Aid Collaboration with the World Federation of Hemophilia (WFH), and My Life Our Future, a population-wide genotyping and genomic biobank initiative. Aside from Biogen, Glenn has worked in small, large, public and private biotech/biopharma firms, including Bayer, Inspiration, Avigen, Selective Genetics and Amgen in the areas of tissue regeneration and hematology. He is the co-author of more than 150 scientific papers, has received over 15 patents and is a member of numerous medical and scientific groups, including HTRS, ISTH and ASH. He served on the medical and scientific advisory council, the board of directors and was president of the board of the National Hemophilia Foundation during a span of two decades. Glenn also served on the Blood Products Advisory Committee at the FDA and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He currently serves on the WFH and WFHUSA board of directors. Glenn received an M.D. and a Ph.D. in immunology, both from Case Western Reserve University in Cleveland, and did his postgraduate training in pathology and hematology research at Washington University in St. Louis.
Glenn focuses his free time on humanitarian aid training workshops in the developing world with WFH, and enjoys wildlife photography.